-
Protease Inhibitor Cocktail: Plant Protein Stability
2026-09-21
Learn how Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1011, can reduce proteolytic variability in plant lysates used for protein-based viability, proliferation, and cytotoxicity studies. This scenario-based guide covers compatibility, dosing, interpretation, and practical vendor selection.
-
CKI 7 dihydrochloride: CK1 Assay Guide
2026-09-20
CKI 7 dihydrochloride enables pathway-focused Casein kinase 1 inhibitor experiments spanning Wnt signaling, apoptosis, circadian biology, and cancer models. This guide separates direct CK1 mechanism testing from the MAPK10–KRT16 metastasis findings and provides practical dosing, controls, and troubleshooting strategies.
-
DAPT (GSI-IX): Mechanism, Uses, and Benchmarks
2026-09-19
DAPT, also called GSI-IX, is a selective γ-secretase inhibitor that reduces amyloid-β generation and modulates Notch signaling. This article connects its biochemical benchmarks with thymic epithelial cell programming, practical assay design, and research-use limitations.
-
Gap19: From Cx43 Selectivity to Assay Design
2026-09-19
Gap19 is a selective connexin 43 hemichannel blocker for separating Cx43 hemichannel signaling from gap junction communication. This article develops an assay-centered framework linking astrocyte ATP release, macrophage NF-κB biology, and neuroprotection in cerebral ischemia.
-
HLY78: A Mechanistic Guide to Wnt Assays
2026-09-18
HLY78 is a ligand-dependent Wnt/β-catenin pathway modulator that links Axin–LRP6 biology to developmental and fibrosis research. This guide interprets the SFRP1 oral submucous fibrosis study to help researchers design better controls, select proximal and distal readouts, and avoid misreading pathway activation as an anti-fibrotic effect.
-
STAMBPL1/TRIM21–AXL Control in KIRC
2026-09-18
The reference study identifies a STAMBPL1/TRIM21/AXL axis that links ubiquitin-dependent protein stability with mesenchymal plasticity and immune evasion in kidney renal clear cell carcinoma. Its findings suggest that STAMBPL1 suppression may improve responses to PD-1 blockade and strengthen sunitinib activity, while also defining important experimental limits for translation.
-
STING agonist-1: Assay Design for B-Cell Immunity
2026-09-17
STING agonist-1 enables controlled investigation of STING pathway activation in innate immunity and IRF4-linked B-cell responses. This article converts recent ESCC findings into a practical assay-design framework for cancer immunotherapy research, with emphasis on causal controls, temporal readouts, and compound handling.
-
Pitavastatin (NK-104): In Vitro Workflow
2026-09-17
Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibitor for controlled studies of cholesterol biosynthesis in cellular and biochemical systems. It is suitable for exploratory in vitro work, but the available dossier does not establish clinical dosing, animal protocols, or a directly matched paper outcome for a specific model.
-
Triazole ALDH2 Activators Protect Ischemic Myocardium
2026-09-16
The reference study used molecular simulation and medicinal chemistry to develop triazole-based activators of aldehyde dehydrogenase 2 (ALDH2), addressing the limited solubility and moderate activity of earlier compounds. Lead compound Z17 produced strong ALDH2 activation and improved cardiac function and biochemical injury markers in a mouse ischemia-reperfusion model, supporting further preclinical development.
-
Sulfo-NHS-Biotin: From Chemistry to Assay Design
2026-09-15
Sulfo-NHS-Biotin is more than a membrane-impermeant labeling reagent: its reaction chemistry, spacer length, and capture format shape assay interpretation. This guide connects amine-reactive biotinylation with practical assay architecture and insights from a biotin-functionalized microsphere study.
-
AP-2α, MGMT, and TMZ Resistance in Recurrent GBM
2026-09-15
The reference study identifies AP-2α as a transcriptional suppressor of MGMT in recurrent glioblastoma and links this pathway to temozolomide sensitivity. By combining promoter-binding assays, DNA-damage measurements, cell models, and an intracranial relapsed-glioma model, the work connects transcriptional regulation with therapeutic response.
-
Hypoxia and Immunometabolism in the Tumor Microenvironment
2026-09-14
This Cancer Letters review presents hypoxia and immune-cell metabolism as mutually reinforcing processes that organize metabolic competition, immune dysfunction, and tumor progression. Its main contribution is an integrative framework for connecting oxygen limitation, nutrient use, immune phenotypes, and metabolism-directed therapeutic strategies.
-
PNU 74654 for Wnt Pathway Assays
2026-09-14
PNU 74654 provides a soluble-in-DMSO chemical tool for time-controlled Wnt/β-catenin pathway perturbation in cancer, stem cell, and differentiation assays. This guide translates the WNT5a/GSK3/β-catenin literature into practical workflows while separating evidence-based findings from assay-development recommendations.
-
PMSF in Epigenetic and Extracellular Vesicle Studies
2026-09-13
Discover how Phenylmethanesulfonyl fluoride (PMSF) can strengthen proteome-preservation strategies in shrimp hemocyte, epigenetic, and extracellular vesicle research. This guide connects selective serine protease inhibition with time-resolved assay design while defining PMSF’s important limitations.
-
10 mM dNTP Mixture for PCR and DNA Synthesis
2026-09-12
The 10 mM dNTP mixture is an equimolar aqueous PCR nucleotide mix containing dATP, dCTP, dGTP, and dTTP at 10 mM each. Its pH 7.0 formulation and storage guidance support reproducible DNA synthesis, while the cited LNP study defines a separate delivery context rather than evidence for dNTP-mediated intracellular transport.